Trial Profile

A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 29 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary)
Indications Carcinoma; Non-small cell lung cancer
Focus Therapeutic Use
Acronyms ADJUVANT; ADJUVANT BR.31

Most Recent Events

25 Jun 2024 Primary endpoint (Compare Disease free survival (DFS) for patients with NSCLC that is PD-L1 expression TC 25%, in patients with PD-L1 expression TC 1%) has not been met, as per results present in the AstraZeneca Media Release.
25 Jun 2024 Results published in the AstraZeneca Media Release
28 Mar 2023 Planned End Date changed from 31 Mar 2025 to 31 Jan 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com